BHIVA Best of CROI Feedback Meetings. London Birmingham North West England Cardiff Gateshead Edinburgh

Size: px
Start display at page:

Download "BHIVA Best of CROI Feedback Meetings. London Birmingham North West England Cardiff Gateshead Edinburgh"

Transcription

1 BHIVA Best of CROI Feedback Meetings London Birmingham North West England Cardiff Gateshead Edinburgh BHIVA Best of CROI Feedback Meetings 2010

2 COMPLICATIONS OF HIV DISEASE AND TREATMENT

3 Overview Cardiovascular Lipodystrophy Renal Bone Neurocognitive impairment

4 DAD study: Impact of Triglycerides on risk of MI Relative risk was small and clinically insignificant Use of drugs unlikely to have any impact on the outcome Finding similar to general population Worm S, DAD study group, Abs: 127

5 Smoking cessation decreases MI risk: DAD Study

6

7 Cardiovascular disease Summary Elevated triglycerides associated with small increase in risk of MI but not clinically significant (DAD: Abs 127) Smoking cessation associated with decreased risk of MI but not mortality (DAD: Abs 124) HIV associated with increased atherosclerosis compared to HIV negative controls. HAART improves this but does not return to health. ( Abs: 125,126) See also session 33: Progression of atherosclerosis: role of inflammation and T cell activation (Abs )

8 EUROSIDA: Cumulative exposure to ARVs and risk of CKD - Multivariate analysis IRR/year 95% CI P-value Tenofovir < Indinavir < Atazanavir Lopinavir/r Adjusted for: baseline egfr, AIDS, age, current CD4, HIV RNA, any cardiovascular event, nephrotoxic drugs, diabetes, hypertension, HCV, gender, non-aids malignancy No other ARVs or regimens associated with CKD Overall incidence of CKD: 1.1 ( )/ 100 PYFU CKD: egfr progression to <60 or 25% decrease if egfr <60 at baseline CROI Abs 107Lb

9 Change in Calculated Creatinine Clearance, (ml/min) A5202: Overall: As-Treated ATV/r vs. EFV Median Change in Creatinine Clearance Wk 48, p=0.17 Wk 96, p=0.33 Week 48 Week 96 Wk 48, p=0.001 Wk 96, p<0.001 p-values: ATV/r vs. EFV ATV/r ATV/r EFV EFV ABC/3TC TDF/FTC N= CROI 2010 Abs 59 Lb

10 Fractional Excretion of Phosphate (%) Plasma Phosphate (mg/dl) Plasma Phosphate (mmol/l) Abs 737 Plasma Phosphate Distribution by Proteinuria Classification Tubular or glomerula r pathology Number of patients Mean uacr (mg/m mol) [NR: < 3.5 mg/mm ol] Mean upcr (mg/m mol) [NR: < 30 mg/mm ol] Mean uacr/ upcr ratio (%) Tubular Possible tubular Glomerul ar Normal Normal Trivial Tubular Glomerular Proteinuria Classification Fractional Excretion of Phosphate by Proteinuria Classification Trivial Tubular Glomerular Proteinuria Classification 8 patients had a renal biopsy; all biopsy results correlated with our definitions of proteinuria Conclusions High upcr, low uacr, low plasma phosphate and high fractional excretion of phosphate are useful in identifying patients with tubular proteinuria In patients with heavy proteinuria measuring both upcr and uacr assists in diagnosing type of renal disease and identifies those in whom a renal biopsy may be useful

11 Mean Change Estimated GFR (ml/min; Cockcroft-Gault) Actual GFR (ml/min; Iohexol) Abs 58Lb: Renal Study of GS-9350 Without ARVs in Healthy Volunteers GS-9350 Alters Estimated GFR Not Actual GFR Placebo GS mg Dosing Day Study of GS-9350 (no ARVs) in healthy volunteers Administered GS-9350 or placebo for 7 days Measured serum creatinine and iohexol clearance concurrently GS-9350 is associated with lower estimated GFR Onset in days, reversible in days GS-9350 has no effect on actual GFR 50 0 BL GS-9350 Day 7 Day 14 BL Placebo n=12 n=12 Day 7 Day 14

12 Renal Summary Exposure to Indinavir, Tenofovir and Atazanavir associated with increased risk of CKD (EUROSIDA) Abs 107 Lb Atazanavir/r +FTC/TDF associated with decreased egfr (Abs 59Lb) Gilead enhancer (GS 9350) associated with decreased egfr but no change in true GFR.Abs 58Lb Measurement of up/c and ualb/c helpful in differentiation between tubular and glomerular disease (Abs 737)

13 % Limb fat loss from 0 to 96 weeks TDF/FTC +EFV (n=56) TDF/FTC +ATV/r (n=45) ABC/3TC +EFV (n=53) ABC/3TC +ATV/r (n=49) Total (n=203) 10% Primary 14.3% 15.6% 18.9% 16.3% (7.5%,28.8%) 16.3% (6.4%,25.3%) (7.0%,28.6%) (9.4%, 31.6%) (11.8%, 22.0%) 20% Post hoc 8.9% 0% 3.8% 6.1% 4.9% No statistically significant differences between NRTI components and NNRTI/PI components (Fisher s exact test) CROI 2010 Abs 106Lb A5224s

14 * * * -linear regression No significant interaction of NRTI and NNRTI/PI components (p=0.82) A5224s

15 * * * -linear regression No significant interaction of NRTI and NNRTI/PI components (p=0.95) A5224s

16 Lipodystrophy ACTG 5224S main findings: Regimens containing TDF/FTC or ABC/3TC increased limb fat and trunk fat and were not significantly different ATV/r led to greater gain in limb fat and trunk fat than EFV Lipoatrophy, even the mild protocol-defined form, occurred in 16% (95% CI %) of the participants and was not significantly different between TDF/FTC and ABC/3TC or between EFV and ATV/r CROI 20210: Abs 106Lb

17 * * * -linear regression No significant interaction of NRTI and NNRTI/PI components (p=0.63) CROI 2010: Abs 106Lb) A5224s

18 A5224s (n=269) 5.6% had 1 fracture (all traumatic) No statistically significant differences between NRTI components or NNRTI/PI components in fracture rate (Fisher s exact) or time to first fracture (log-rank test) A5202 (n=1857) 4.3% fracture rate (12.7% of those atraumatic) No statistically significant differences between NRTI components or NNRTI/PI components in fracture rate (Fisher s exact), incidence or time to first fracture (log-rank test) TDF/FTC+ EFV (n=464) TDF/FTC+ ATV/r (n=465) ABC/3TC+E FV (n=465) ABC/3TC+A TV/r (n=463) Total (n=1857) % with 1 fractures 4.5% 4.5% 4.7% 3.4% 4.3% Incidence per 100 pt-year A5224s

19 HOPS: prospective cohort study in 10 clinics in 8 cities in USA : Started in 1993 Over 5800 patients followed from 2000 to (4%) had fracture Median age 45 years 76% were male Age over 47, Nadir CD4, diabetes and Hep-C predicted fracture Crude rates of fractures (95% CI) amng HOPS patients No data on BMD Increase fracture could be due to increased awareness or patients living longer Dao C et al, abs:128

20 Fragility fracture common in HIV patients VACS: prospective observational study From 1997 to 2009 (ICD9) Restricted to male Median age 54 Over 119,000 and 34% were HIV positive Older age, CVA, alcohol use, Black ethnicity and cachexia were predictable factors

21 Bone Summary HIV infection associated with increased fracture rate (HOPS, Abs: 128) Fractures more common in male with older age group (VACS, Abs:129) Fracture rates not increased in younger HIV +ve woman (Abs: 130 WIHS) No difference in incidence of fractures between FTC/TDF and ABC/3TC and between ATV/r and EFV, though significant difference in BMD between NRTI backbone (ACTG 5224S, Abs 106Lb)

22 Neurology

23 CHARTER study: Correlates of CSF viral load N: 1221, 31% not on ART, 78% with CSF and plasma VL, crossectional analysis Higher plasma viral load strongest correlate of higher CSF VL both on and off ART Off ART: high CSF viral load associated with older age, lower CD4 count and lower nadir CD4 count. On ART: detectable CSF VL associated with poor adherence, lower CPE score of ART, CD4 count <200 and non-white ethnicity Higher CSF viral load alone not associated with worse NP performance CSF VL greater than plasma viral load (13%) was associated with worse NP performance. On ART with plasma VL <50, only 4% had detectable CSF VL and not correlated with clinical outcome Letendre S, abs:172

24 Higher CD-4 nadir associated better cognitive performance: to consider starting early treatment: CHARTER Study Ellis R, abs:429

25 Neurology issues: Summary CHARTER study Compared to CD4 nadir <50, higher nadir CD-4 is associated with reduced risk of HAND: CD4 nadir >350, OR: 0.62 ( ) (Abs: 429) Plasma viral suppression correlates with CSF viral suppression. With ART detectable CSF viral load associated with poor adherence, worse CPE and white ethnicity: cross-sectional study (n=1221) (Abs: 172) Similar findings: Stable ART and good CNS penetration associated with better NP performance (Abs:432 and 433)

26 CPE revised ranks and CSF detectable viral load Revised CPE table, 2010 CSF viral load as such was not predictive But CSF viral load above or equal to plasma VL had worse NP performance Letendre S, abs:172

27 BHIVA Best of CROI Feedback Meetings London Birmingham North West England Cardiff Gateshead Edinburgh BHIVA Best of CROI Feedback Meetings 2010

COMPETING INTEREST OF FINANCIAL VALUE

COMPETING INTEREST OF FINANCIAL VALUE BHIVA AUTUMN CONFERENCE 2012 Including CHIVA Parallel Sessions Dr Ian Williams University College London Medical School COMPETING INTEREST OF FINANCIAL VALUE > 1,000: Speaker Name Statement Ian Williams

More information

The impact of antiretroviral drugs on renal function

The impact of antiretroviral drugs on renal function The impact of antiretroviral drugs on renal function Professor Bruce Hendry Renal Medicine King s College London King s College Hospital NHS Foundation Trust 1 DISCLOSURES: BRUCE HENDRY I have received

More information

Prevalence of Comorbidities among HIV-positive patients in Taiwan

Prevalence of Comorbidities among HIV-positive patients in Taiwan Prevalence of Comorbidities among HIV-positive patients in Taiwan Chien-Ching Hung, MD, PhD Department of Internal Medicine National Taiwan University Hospital, Taipei, Taiwan % of participants Comorbidity

More information

ART Treatment. ART Treatment

ART Treatment. ART Treatment Naïve Experienced Strategies ARV in pregnancy ART Treatment Naïve studies: ART Treatment Abstract 37 Atazanavir/r vs Lopinavir/r: Castle study Abstract 774 Kivexa vs Truvada: HEAT study Abstract 775 Lopinavir/r

More information

D:A:D: Cumulative Exposure to DRV/r Increase MI Risk

D:A:D: Cumulative Exposure to DRV/r Increase MI Risk D:A:D: Cumulative Exposure to DRV/r Increase MI Risk 20.0-15.0-10.0-5.0-4.0-3.0-2.0-1.0- Unadjusted CVD rate ratios per 5 years additional exposure: ATV/r 1.25 [1.10-1.43] and DRV/r 1.93 [1.63-2.28] Adjusted*

More information

Central Nervous System Penetration of ARVs: Does it Matter?

Central Nervous System Penetration of ARVs: Does it Matter? NORTHWEST AIDS EDUCATION AND TRAINING CENTER Central Nervous System Penetration of ARVs: Does it Matter? Christina M. Marra, MD Neurology and Medicine (Infectious Diseases) University of Washington 15

More information

STRIBILD (aka. The Quad Pill)

STRIBILD (aka. The Quad Pill) NORTHWEST AIDS EDUCATION AND TRAINING CENTER STRIBILD (aka. The Quad Pill) Brian R. Wood, MD Medical Director, NW AETC ECHO Assistant Professor of Medicine, University of Washington Presentation prepared

More information

Sources of slides and information. roi/main.html. CME slide kit : Rush University Medical Center

Sources of slides and information. roi/main.html. CME slide kit : Rush University Medical Center Sources of slides and information www.clinicaloptions.com/hiv com/hiv http://www.hivandhepatitis.com/2010_conference/chivandhepatitis conference/c roi/main.html CME slide kit : Rush University Medical

More information

Report Back from CROI 2010

Report Back from CROI 2010 Report Back from CROI 2010 Conference on Retroviruses and Opportunistic Infections Edwin Charlebois, MPH PhD Associate Professor of Medicine Department of Medicine University of California, San Francisco

More information

Fat redistribution on ARVs: dogma versus data

Fat redistribution on ARVs: dogma versus data Fat redistribution on ARVs: dogma versus data Gary Maartens Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN KAAPSTAD Half of what we are going to teach

More information

BHIVA Best of CROI Feedback Meetings. London Birmingham North West England Cardiff Gateshead Edinburgh

BHIVA Best of CROI Feedback Meetings. London Birmingham North West England Cardiff Gateshead Edinburgh BHIVA Best of CROI Feedback Meetings London Birmingham North West England Cardiff Gateshead Edinburgh BHIVA Best of CROI Feedback Meetings 2010 ANTIRETROVIRAL TREATMENT STRATEGIES AND NEW DRUGS A5202:

More information

C Orkin, 1 G Moyle, 2 M Fisher, 3 H Wang, 4 J Ewan 4 and ROCKET I Study Group. Chelsea and Westminster Hospital, London, UK;

C Orkin, 1 G Moyle, 2 M Fisher, 3 H Wang, 4 J Ewan 4 and ROCKET I Study Group. Chelsea and Westminster Hospital, London, UK; Switching from Kivexa [KVX] (ABC/3TC) + Efavirenz [EFV] to [ATR] (EFV/FTC/TDF) Reduces Cholesterol in Hypercholesterolaemic Subjects: Primary Endpoint Results of a 24- Week Randomised Study C Orkin, 1

More information

Slide #1 Case Presentation: Kidney Disease

Slide #1 Case Presentation: Kidney Disease Slide #1 Case Presentation: Kidney Disease Christina Wyatt, MD Mount Sinai, New York Slide #2 Disclosures Investigator-initiated research support Gilead Sciences Honoraria for internal education Bristol

More information

Real Life Experience of Dolutegravir and Lamivudine Dual Therapy As a Switching Regimen in HIVTR Cohort

Real Life Experience of Dolutegravir and Lamivudine Dual Therapy As a Switching Regimen in HIVTR Cohort Real Life Experience of Dolutegravir and Lamivudine Dual Therapy As a Switching Regimen in HIVTR Cohort Yagci-Caglayik D 1, Gokengin D 2, Inan A 3, Ozkan-Ozdemir H 4, Inan D 5, Akbulut A 6, Korten V 1,

More information

Antiretroviral Therapy: What to Start

Antiretroviral Therapy: What to Start FLOWED: 05-14-2015 Chicago, IL: May 18, 2015 Antiretroviral Therapy: What to Start Eric S. Daar, MD Professor of Medicine David Geffen School of Medicine University of California Los Angeles Los Angeles,

More information

TDF containing ART: Efficacy and Safety. Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia

TDF containing ART: Efficacy and Safety. Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia TDF containing ART: Efficacy and Safety Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia 1 Indications Treatment of HIV-1 in combination with other antiretroviral

More information

HIV and Bone Disease: Through Thick and Thin! Pablo Tebas, MD

HIV and Bone Disease: Through Thick and Thin! Pablo Tebas, MD HIV and Bone Disease: Through Thick and Thin! Pablo Tebas, MD April 30 th, 2016 Disclosures I serve in an adjudication panel in a VZV vaccine study (Glaxo) I consult for Merck My research is supported

More information

Infertility Treatment and HIV

Infertility Treatment and HIV Infertility Treatment and HIV Infertility Treatment by IVF Or Intra-cytoplasmic Sperm Injections (ICSC) In Chronic HIV-1 Sero- discordant Couples (Poster 670) Retrospective study of outcome of IVF or ICSC

More information

Novedades en el tratamiento de la hepatitis B: noticias desde la EASL. Maria Buti Hospital Universitario Valle Hebrón Barcelona

Novedades en el tratamiento de la hepatitis B: noticias desde la EASL. Maria Buti Hospital Universitario Valle Hebrón Barcelona Novedades en el tratamiento de la hepatitis B: noticias desde la EASL Maria Buti Hospital Universitario Valle Hebrón Barcelona Milestones in CHB treatment Conventional IFN 1991 Lamivudine (LAM) 1998 Adefovir

More information

Professor Jeffery Lennox

Professor Jeffery Lennox BHIVA AUTUMN CONFERENCE 2014 Including CHIVA Parallel Sessions Professor Jeffery Lennox Emory University School of Medicine Atlanta, Georgia, USA 9-10 October 2014, Queen Elizabeth II Conference Centre,

More information

Abstract PS8/2. Double-blind treatment phase D/C/F/TAF. + matching D/C + F/TDF placebo D/C/F/TAF. D/C + F/TDF + matching D/C/F/TAF placebo

Abstract PS8/2. Double-blind treatment phase D/C/F/TAF. + matching D/C + F/TDF placebo D/C/F/TAF. D/C + F/TDF + matching D/C/F/TAF placebo WEEK 8 RESULTS OF AMBER: A PHASE 3, RANDOMISED, DOUBLE-BLIND TRIAL IN ANTIRETROVIRAL TREATMENT (ART)-NAÏVE HIV--INFECTED ADULTS TO EVALUATE THE EFFICACY AND SAFETY OF THE ONCE-DAILY, SINGLE-TABLET REGIMEN

More information

12th European AIDS Conference / EACS ARV Therapies and Therapeutic Strategies A CME Newsletter

12th European AIDS Conference / EACS ARV Therapies and Therapeutic Strategies A CME Newsletter EACS 2009 11-14, November 2009 Cologne, Germany Course Director Jürgen K. Rockstroh, MD Co-Chairman, 12th European AIDS Conference Professor, University of Bonn Bonn, Germany Faculty Calvin Cohen, MD,

More information

Clinical Case. Christophe Hézode, Henri Mondor Hospital, Paris-Est University, Créteil, France

Clinical Case. Christophe Hézode, Henri Mondor Hospital, Paris-Est University, Créteil, France Clinical Case Christophe Hézode, Henri Mondor Hospital, Paris-Est University, Créteil, France Paris, January 16th 2018 Links of interest and Disclaimer Adviser, speaker, investigator for: Abbvie, BMS,

More information

Protease Inhibitors and Renal Function in Patients with HIV Infection: a Systematic Review

Protease Inhibitors and Renal Function in Patients with HIV Infection: a Systematic Review Infect Dis Ther (2015) 4:15 50 DOI 10.1007/s40121-014-0056-4 REVIEW Protease Inhibitors and Renal Function in Patients with HIV Infection: a Systematic Review Corinne Isnard Bagnis Hans-Jürgen Stellbrink

More information

The 17th Conference on Retroviruses and Opportunistic Infections* ARV Therapies and Therapeutic Strategies A CME Newsletter

The 17th Conference on Retroviruses and Opportunistic Infections* ARV Therapies and Therapeutic Strategies A CME Newsletter * CROI 2010 * February 16-19, 2010 San Francisco, CA Course Director Calvin Cohen, MD, MS Research Director, CRI New England Clinical Instructor, Harvard Medical School Boston, Massachusetts Faculty Jürgen

More information

Update on HIV-Related Kidney Diseases. Agenda

Update on HIV-Related Kidney Diseases. Agenda Update on HIV-Related Kidney Diseases ANDY CHOI THE MEDICAL MANAGEMENT OF HIV/AIDS DECEMBER 15, 2006 Agenda 1. EPIDEMIOLOGY: A) END STAGE RENAL DISEASE (ESRD) B) CHRONIC KIDNEY DISEASE (CKD) 2. HIV-ASSOCIATED

More information

Antiretroviral Therapy: Current Recommendations, New Drugs, and Novel Strategies. Joel Gallant, MD, MPH Johns Hopkins University School of Medicine

Antiretroviral Therapy: Current Recommendations, New Drugs, and Novel Strategies. Joel Gallant, MD, MPH Johns Hopkins University School of Medicine Antiretroviral Therapy: Current Recommendations, New Drugs, and Novel Strategies Joel Gallant, MD, MPH Johns Hopkins University School of Medicine Initial Regimen: DHHS Guidelines 3/27/2012 Preferred Regimens

More information

HIV and the Central Nervous System Impact of Drug Distribution Scott L. Letendre, MD. Professor of Medicine University of California, San Diego

HIV and the Central Nervous System Impact of Drug Distribution Scott L. Letendre, MD. Professor of Medicine University of California, San Diego HIV and the Central Nervous System Impact of Drug Distribution Scott L. Letendre, MD Professor of Medicine University of California, San Diego Disclosures Grant/research support Abbvie Gilead Sciences

More information

Professor Anna Maria Geretti

Professor Anna Maria Geretti THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014 Professor Anna Maria Geretti Institute of Infection & Global Health, University of Liverpool 1-4 April 2014, Arena and Convention Centre Liverpool THIRD JOINT

More information

Dr Alan Winston. Imperial College Healthcare NHS Trust London. 7-8 October 2010, Queen Elizabeth II Conference Centre, London.

Dr Alan Winston. Imperial College Healthcare NHS Trust London. 7-8 October 2010, Queen Elizabeth II Conference Centre, London. BHIVA AUTUMN CONFERENCE 2010 Including CHIVA Parallel Sessions Dr Alan Winston Imperial College Healthcare NHS Trust London 7-8 October 2010, Queen Elizabeth II Conference Centre, London BHIVA AUTUMN CONFERENCE

More information

Chan HLY, Chan CK, Hui AJ, et al. Tenofovir Disoproxil Fumarate in Chronic HBV Infected Patients with Normal ALT and High HBV DNA Levels

Chan HLY, Chan CK, Hui AJ, et al. Tenofovir Disoproxil Fumarate in Chronic HBV Infected Patients with Normal ALT and High HBV DNA Levels Online supplement to: Chan HLY, Chan CK, Hui AJ, et al. Tenofovir Disoproxil Fumarate in Chronic HBV Infected Patients with Normal ALT and High HBV DNA Levels Supplementary Figure 1. CONSORT disposition

More information

HIV DISEASE! Neurobehavioral! Neuromedical. Igor Grant, MD, FRCP(C) Director HIV Neurobehavioral Research Program University of California, San Diego

HIV DISEASE! Neurobehavioral! Neuromedical. Igor Grant, MD, FRCP(C) Director HIV Neurobehavioral Research Program University of California, San Diego Igor Grant, MD, FRCP(C) Director HIV Neurobehavioral Research Program University of California, San Diego HIV DISEASE! Neuromedical Neurobehavioral! HIV Neurobehavioral Disturbances HIV Associated Neurocognitive

More information

Virological suppression and PIs. Diego Ripamonti Malattie Infettive - Bergamo

Virological suppression and PIs. Diego Ripamonti Malattie Infettive - Bergamo Virological suppression and PIs Diego Ripamonti Malattie Infettive - Bergamo Ritonavir-boosted PIs Boosted PIs: 3 drugs in one The intrinsic antiretroviral activity Viral suppression and high baseline

More information

Professor José Arribas

Professor José Arribas 19 th Annual Conference of the British HIV Association (BHIVA) Professor José Arribas Hospital La Paz, Madrid, Spain 16-19 April 2013, Manchester Central Convention Complex Can we live without nucleosides?

More information

Treating HIV: When the Guidelines Don t Fit. Joel Gallant, MD, MPH. Southwest CARE Center Santa Fe, New Mexico

Treating HIV: When the Guidelines Don t Fit. Joel Gallant, MD, MPH. Southwest CARE Center Santa Fe, New Mexico Treating HIV: When the Guidelines Don t Fit Joel Gallant, MD, MPH Southwest CARE Center Santa Fe, New Mexico Johns Hopkins University School of Medicine University of New Mexico School of Medicine Disclosures

More information

WHEN TO START? CROI 2015: Focus on ART

WHEN TO START? CROI 2015: Focus on ART CROI 215: Focus on ART FORMATTED: 4-1-15 Washington, DC: May 13, 215 Roy M. Gulick, MD, MPH Gladys and Roland Harriman Professor of Medicine Chief, Division of Infectious Diseases Weill Cornell Medical

More information

Case 1 continued. Case 1 (cont) 12/8/16. MMAH Debate Panel Thursday, December 8, Case 1

Case 1 continued. Case 1 (cont) 12/8/16. MMAH Debate Panel Thursday, December 8, Case 1 MMAH Debate Panel Thursday, December 8, 2016 Case 1 HPI 55 yo man with newly diagnosed HIV initiates care in your clinic. His CD4+ cell count is 600, with HIV VL=90,000 copies/ml. He is asymptomatic at

More information

More Options, Some Opinions Initial Therapies for HIV Judith S. Currier, MD

More Options, Some Opinions Initial Therapies for HIV Judith S. Currier, MD More Options, Some Opinions Initial Therapies for HIV Judith S. Currier, MD More Options, Some Opinions: Initial Therapies for HIV Judith S. Currier, MD University of California Los Angeles Los Angeles,

More information

2/10/2015. Switching from old regimens. HIV treatment revision: As simple as old versus new? What is an old regimen? What is an old regimen?

2/10/2015. Switching from old regimens. HIV treatment revision: As simple as old versus new? What is an old regimen? What is an old regimen? Switching from old regimens David Nolan Department of Immunology, Royal Perth Hospital, Western Australia Institute for Immunology and Infectious Diseases, Murdoch University, Western Australia What is

More information

COMPETING INTEREST OF FINANCIAL VALUE

COMPETING INTEREST OF FINANCIAL VALUE BHIVA AUTUMN CONFERENCE 2012 Including CHIVA Parallel Sessions Dr Duncan Churchill Royal Sussex County Hospital, Brighton COMPETING INTEREST OF FINANCIAL VALUE > 1,000: Speaker Name Statement Duncan Churchill

More information

TDF Renal Dysfunction

TDF Renal Dysfunction TDF Renal Dysfunction Sarala Naicker MBChB, FRCP, PhD Division of Nephrology Dept of Internal Medicine University of the Witwatersrand Johannesburg South Africa SA HIV Clinician Society Conference Cape

More information

Supplementary Data. Supplementary Table S2. Antiretroviral Therapies Taken with Ledipasvir/Sofosbuvir

Supplementary Data. Supplementary Table S2. Antiretroviral Therapies Taken with Ledipasvir/Sofosbuvir Supplementary Data Statistical Analysis Due to the limited number of patients with acute kidney injury and concern for model overfitting, covariates included in multivariable logistic regression analyses

More information

ASSOCIATION BETWEEN CARDIOVASCULAR DISEASE & CONTEMPORARILY USED PROTEASE INHIBITORS

ASSOCIATION BETWEEN CARDIOVASCULAR DISEASE & CONTEMPORARILY USED PROTEASE INHIBITORS ASSOCIATION BETWEEN CARDIOVASCULAR DISEASE & CONTEMPORARILY USED PROTEASE INHIBITORS L Ryom, JD Lundgren, W El-Sadr, P Reiss, A Phillips, O Kirk, R Weber, E Fontas, AD Monforte, S de Wit, F Dabis, CI Hatleberg,

More information

Switching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches

Switching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches Switching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches Harry W. Lampiris, MD Chief, Infectious Disease Section, San Francisco VA Medical Center Professor

More information

HIV associated CNS disease in the era of HAART

HIV associated CNS disease in the era of HAART HIV associated CNS disease in the era of HAART CSF/CNS penetration and efficacy Acknowledgements Peter Portegies Department of Neurology, AMC Mark van der Valk Department of Internal Medicine/Infectious

More information

Antiretroviral Treatment 2014

Antiretroviral Treatment 2014 Activity Code FM285 Antiretroviral Treatment 2014 Rajesh Gandhi, MD Masssachusetts General Hospital Disclosures: Educational grants to my institution from Janssen, Viiv, Abbott Learning Objectives Upon

More information

HIV, Co-morbidity and Ageing

HIV, Co-morbidity and Ageing HIV, Co-morbidity and Ageing A good head and a good heart are always a formidable combination V Encuentro de Salud Pública 8 October 2015, Madrid, Spain Peter Reiss Director HIV Monitoring Foundation Professor

More information

Terapia Antirretroviral en la Infección por el VIH (problemas, retos y soluciones) Dr. Jose R

Terapia Antirretroviral en la Infección por el VIH (problemas, retos y soluciones) Dr. Jose R Terapia Antirretroviral en la Infección por el VIH (problemas, retos y soluciones) Dr. Jose R Arribas @jrarribas Disclosures Speaker s Bureau: Gilead Board Member/Advisory Panel: MSD, Gilead, Janssen,

More information

Didactic Series. HIV-Associated Renal Disease. Christian B. Ramers, MD, MPH Family Health Centers of San Diego Ciaccio Memorial Clinic 10/9/14

Didactic Series. HIV-Associated Renal Disease. Christian B. Ramers, MD, MPH Family Health Centers of San Diego Ciaccio Memorial Clinic 10/9/14 Didactic Series HIV-Associated Renal Disease Christian B. Ramers, MD, MPH Family Health Centers of San Diego Ciaccio Memorial Clinic 10/9/14 ACCREDITATION STATEMENT: University of California, San Diego

More information

Tenofovir Alafenamide (TAF)

Tenofovir Alafenamide (TAF) Frontier AIDS Education and Training Center Tenofovir Alafenamide (TAF) Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical Director, Frontier AETC ECHO January 28, 2016

More information

REASONS FOR DISCONTINUATION OF DUAL THERAPY WITH DOLUTEGRAVIR AND RILPIVIRINE

REASONS FOR DISCONTINUATION OF DUAL THERAPY WITH DOLUTEGRAVIR AND RILPIVIRINE REASONS FOR DISCONTINUATION OF DUAL THERAPY WITH DOLUTEGRAVIR AND RILPIVIRINE R. Montejano, N. Stella-Ascariz, S. Garcia-Bujalance, JI. Bernardino, V. Hontañon, R. Mican, Montes M, E. Valencia, J. González,

More information

Distribution and Effectiveness of Antiretrovirals in the Central Nervous System

Distribution and Effectiveness of Antiretrovirals in the Central Nervous System Distribution and Effectiveness of Antiretrovirals in the Central Nervous System Scott Letendre, MD Associate Professor of Medicine HIV Neurobehavioral Research Center and Antiviral Research Center University

More information

Chronic complications of HIV infection. An update Pablo Tebas, MD

Chronic complications of HIV infection. An update Pablo Tebas, MD Activity Code TM809 Chronic complications of HIV infection. An update 2014 Pablo Tebas, MD Learning Objectives Upon completion of this presentation, learners should be better able to: Identify and update

More information

Safety Profile of Viread and Truvada. Ian McGowan, MD PhD FRCP Cape Town MTN Regional Meeting September, 2008

Safety Profile of Viread and Truvada. Ian McGowan, MD PhD FRCP Cape Town MTN Regional Meeting September, 2008 Safety Profile of Viread and Truvada Ian McGowan, MD PhD FRCP Cape Town MTN Regional Meeting September, 2008 Overview Safety assessment in drug development Physiology 101 Renal Bone Liver Safety profile

More information

Complications and adverse reactions associated with antiretroviral therapy

Complications and adverse reactions associated with antiretroviral therapy 13th International Workshop on Clinical Pharmacology of HIV Therapy Barcelona, April 16 2012 Complications and adverse reactions associated with antiretroviral therapy Esteban Martinez 1. Long-term adverse

More information

AGING KIDNEY IN HIV DISEASE

AGING KIDNEY IN HIV DISEASE AGING KIDNEY IN HIV DISEASE Michael G. Shlipak, MD, MPH Professor of Medicine, Epidemiology and Biostatistics, UCSF Chief, General Internal Medicine, San Francisco VA Medical Center Kidney, Aging and HIV

More information

Dr Michael Rayment Chelsea and Westminster Hospital, London

Dr Michael Rayment Chelsea and Westminster Hospital, London 17 TH ANNUAL CONFERENCE OF THE BRITISH HIV ASSOCIATION (BHIVA) Dr Michael Rayment Chelsea and Westminster Hospital, London 6-8 April 2011, Bournemouth International Centre A decade of renal biopsies in

More information

How to best manage HIV patient?

How to best manage HIV patient? How to best manage HIV patient? 1 2 Treatment Treatment Failure success HIV therapy = a long life therapy Why do we want to change a suppressive ART? Side effect Comorbidities Reduce drug burden How to

More information

Novedades en la prevención y control de las comorbilidades asociadas al VIH

Novedades en la prevención y control de las comorbilidades asociadas al VIH IX Congreso Nacional GeSIDA Vigo, 28 Noviembre-1 Diciembre 2017 Novedades en la prevención y control de las comorbilidades asociadas al VIH Esteban Martinez estebanm@clinic.ub.es Comorbidities in HIV+

More information

HIV Infection as a Chronic Disease. Howard Libman, MD Beth Israel Deaconess Medical Center Harvard Medical School

HIV Infection as a Chronic Disease. Howard Libman, MD Beth Israel Deaconess Medical Center Harvard Medical School HIV Infection as a Chronic Disease Howard Libman, MD Beth Israel Deaconess Medical Center Harvard Medical School Role of Primary Care Approximately 50,000 patients are diagnosed with HIV infection annually

More information

Dolutegravir Attributes

Dolutegravir Attributes Dolutegravir (; S/GSK1349572) in Combination Therapy Exhibits Rapid and Sustained Antiviral Response in Antiretroviral Naïve Adults: 96 Week Results from SPRING 1 (ING112276) Hans Juergen Stellbrink, 1

More information

DRUGS IN PIPELINE. Pr JC YOMBI UCL-AIDS REFERENCE CENTRE BREACH Sept 27, 2015

DRUGS IN PIPELINE. Pr JC YOMBI UCL-AIDS REFERENCE CENTRE BREACH Sept 27, 2015 DRUGS IN PIPELINE Pr JC YOMBI UCL-AIDS REFERENCE CENTRE BREACH Sept 27, 2015 N(t)RTI The Development of TAF TAF Delivers the High Potency of TDF While Minimizing Off- Target Kidney and Bone Side Effects

More information

CLINICAL PEARLS OF NEW HIV MEDICATIONS PHARMACIST OBJECTIVES TECHNICIAN OBJECTIVES. At the end of this presentation pharmacists will be able to:

CLINICAL PEARLS OF NEW HIV MEDICATIONS PHARMACIST OBJECTIVES TECHNICIAN OBJECTIVES. At the end of this presentation pharmacists will be able to: CLINICAL PEARLS OF NEW HIV MEDICATIONS Cindy Lou Zoellner, PharmD, BCPS Added Qualifications in Infectious Diseases Senior Clinical Pharmacy Specialist in HIV Parkland Health & Hospital System Volunteer

More information

Didactic Series. Bone Health in the context of HIV. Christian B. Ramers, MD, MPH, AAHIVS Family Health Centers of San Diego 9/22/16

Didactic Series. Bone Health in the context of HIV. Christian B. Ramers, MD, MPH, AAHIVS Family Health Centers of San Diego 9/22/16 Didactic Series Bone Health in the context of HIV Christian B. Ramers, MD, MPH, AAHIVS Family Health Centers of San Diego 9/22/16 This project is supported by the Health Resources and Services Administration

More information

Tra falsi miti e realtà Danno osseo e HIV: ciò che veramente conosciamo. Cristina Gervasoni ASST FBF Sacco

Tra falsi miti e realtà Danno osseo e HIV: ciò che veramente conosciamo. Cristina Gervasoni ASST FBF Sacco Tra falsi miti e realtà Danno osseo e HIV: ciò che veramente conosciamo Cristina Gervasoni ASST FBF Sacco Outline What do I know? What do we know? What have we learned lately? Outline What do we know?

More information

Long term toxicities from antiretrovirals: an inevitable consequence?

Long term toxicities from antiretrovirals: an inevitable consequence? Second Joint Conference 0f the British HIV Association [BHIVA] and the British Association for Sexual Health and HIV [BASHH] 20-23 April 2010, Manchester Central Convention Complex Long term toxicities

More information

Dr Paddy Mallon. Mater Misericordiae University Hospital, Dublin, Ireland. BHIVA AUTUMN CONFERENCE 2014 Including CHIVA Parallel Sessions

Dr Paddy Mallon. Mater Misericordiae University Hospital, Dublin, Ireland. BHIVA AUTUMN CONFERENCE 2014 Including CHIVA Parallel Sessions BHIVA AUTUMN CONFERENCE 2014 Including CHIVA Parallel Sessions Dr Paddy Mallon Mater Misericordiae University Hospital, Dublin, Ireland 9-10 October 2014, Queen Elizabeth II Conference Centre, London BHIVA

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Abacavir is associated with increased risk of cardiovascular disease in HIV-infected patients: A UK clinic case-control study

Abacavir is associated with increased risk of cardiovascular disease in HIV-infected patients: A UK clinic case-control study Abacavir is associated with increased risk of cardiovascular disease in HIV-infected patients: A UK clinic case-control study Collins Iwuji, Duncan Churchill, Yvonne Gilleece, Martin Fisher Brighton and

More information

Immunologic Failure and Chronic Inflammation. Steven G. Deeks Professor of Medicine University of California, San Francisco

Immunologic Failure and Chronic Inflammation. Steven G. Deeks Professor of Medicine University of California, San Francisco Immunologic Failure and Chronic Inflammation Steven G. Deeks Professor of Medicine University of California, San Francisco Plasma HIV RNA (log) 6 5 4 3 2 52 year old HIV+/HCV+ man presents with symptomatic

More information

Differences in Calculated Glomerular Filtration Rates (GFR) in Efavirenz (EFV) or Tenofovir (TDF)-treated Adults in ESS40006

Differences in Calculated Glomerular Filtration Rates (GFR) in Efavirenz (EFV) or Tenofovir (TDF)-treated Adults in ESS40006 13th Conference on Retroviruses and Opportunistic Infections Denver, CO, USA. February 5-9, 2006 Poster Number 777 Differences in Calculated Glomerular Filtration Rates (GFR) in Efavirenz (EFV) or Tenofovir

More information

This is the author s version of a work that was submitted/accepted for publication in the following source:

This is the author s version of a work that was submitted/accepted for publication in the following source: This is the author s version of a work that was submitted/accepted for publication in the following source: Kelly, Mark D., Gibson, Abby, Bartlett, Harry, Rowling, Diane, & Patten, John (2013) Tenofovir-associated

More information

HIV Update. On The Cutting Edge A Chronic Disease. Rhett M Shirley, MD

HIV Update. On The Cutting Edge A Chronic Disease. Rhett M Shirley, MD HIV Update On The Cutting Edge A Chronic Disease Rhett M Shirley, MD CDC Mid-point life expectancy estimates at age 20 years in three calendar periods, overall and by sociodemographic characteristics,

More information

Switching antiretroviral therapy to safer strategies based on integrase inhibitors

Switching antiretroviral therapy to safer strategies based on integrase inhibitors Switching antiretroviral therapy to safer strategies based on integrase inhibitors Dr Paddy Mallon UCD HIV Molecular Research Group UCD School of Medicine paddy.mallon@ucd.ie UCD School of Medicine & Medical

More information

Integrase Strand Transfer Inhibitors on the Horizon

Integrase Strand Transfer Inhibitors on the Horizon NORTHWEST AIDS EDUCATION AND TRAINING CENTER Integrase Strand Transfer Inhibitors on the Horizon David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, University of Washington Presentation

More information

Clinical Pharmacology of DAA s for HCV: What s New & What s In Pipeline

Clinical Pharmacology of DAA s for HCV: What s New & What s In Pipeline Clinical Pharmacology of DAA s for HCV: What s New & What s In Pipeline Kirk Bertelsen, PhD Clinical Pharmacology Janssen Pharmaceuticals, Research & Development 4/24/2013 1 Incivo Simeprevir 2 Janssen

More information

Integrase Inhibitors in the Treatment HIV-Infection. Andrew Zolopa, MD Stanford University

Integrase Inhibitors in the Treatment HIV-Infection. Andrew Zolopa, MD Stanford University Integrase Inhibitors in the Treatment HIV-Infection Andrew Zolopa, MD Stanford University 1 IAS-USA 212 Guidelines Updated Recommendations When to start ART is now recommended for all patients, regardless

More information

HIV and Brain Func.on. Tristan J Barber Research Physician St Stephen s AIDS Trust Chelsea and Westminster Hospital

HIV and Brain Func.on. Tristan J Barber Research Physician St Stephen s AIDS Trust Chelsea and Westminster Hospital HIV and Brain Func.on Tristan J Barber Research Physician St Stephen s AIDS Trust Chelsea and Westminster Hospital HIV and the Brain When can HIV affect the brain? Seroconversion Long term infected (not

More information

4/14/2016. Breaking News From the 2016 Conference on Retroviruses and Opportunistic Infections

4/14/2016. Breaking News From the 2016 Conference on Retroviruses and Opportunistic Infections Breaking News From the 2016 Conference on Retroviruses and Opportunistic Infections Jeffrey L. Lennox, MD Professor of Medicine Associate Dean for Clinical Research Emory University School of Medicine

More information

WESTERN CAPE ART GUIDELINES PRESENTATION 2013

WESTERN CAPE ART GUIDELINES PRESENTATION 2013 WESTERN CAPE ART GUIDELINES PRESENTATION 2013 The WC guidelines are based on SA National ART guidelines dated 24th March 2013 Acknowledgement goes to members of the Adult and Paediatric HAST policy advisory

More information

Didactic Series. CROI 2014 Update. March 27, 2014

Didactic Series. CROI 2014 Update. March 27, 2014 Didactic Series CROI 2014 Update Christian Ramers, MD, MPH Family Health Centers of San Diego Ciaccio Memorial Clinic Jacqueline Peterson Tulsky, MD UCSF Positive Health Program at SFGH Medical Director,

More information

HIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University

HIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start

More information

Treatment update. Bronagh McBrien June 2016

Treatment update. Bronagh McBrien June 2016 Treatment update Bronagh McBrien June 2016 Speaker Name Bronagh McBrien Statement Received educational funding and support from Gilead, Merck, Boehringer Ingelheim, Janssen-Cilag Date : 27 June 2016 BHIVA

More information

IAS 2015: Return to Vancouver

IAS 2015: Return to Vancouver IAS 2015: Return to Vancouver Paul E. Sax, M.D. Clinical Director, Division of Infectious Diseases Brigham and Women s Hospital Professor of Medicine Harvard Medical School NEAETC Memories from 1996 First

More information

Management of patients with antiretroviral treatment failure: guidelines comparison

Management of patients with antiretroviral treatment failure: guidelines comparison The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral

More information

Cardiovascular Complications of HIV and Its Treatment

Cardiovascular Complications of HIV and Its Treatment Cardiovascular Complications of HIV and Its Treatment FORMATTED: 11/6/15 Marshall J. Glesby, MD, PhD Professor of Medicine, Healthcare Policy and Research Weill Cornell College of Medicine New York, New

More information

IAC Analyst Presentation

IAC Analyst Presentation IAC Analyst Presentation David Redfern Chairman, ViiV Healthcare Chief Strategy Officer, GSK July 27, 2012 1 ViiV Healthcare Dr Dominique Limet CEO, ViiV Healthcare July 27, 2012 2 Equity split of 85%

More information

Didactic Series. CROI New Antiretroviral Therapies. Daniel Lee, MD Clinical Professor of Medicine UCSD Medical Center Owen Clinic July 14, 2016

Didactic Series. CROI New Antiretroviral Therapies. Daniel Lee, MD Clinical Professor of Medicine UCSD Medical Center Owen Clinic July 14, 2016 Didactic Series CROI 2016 - New Antiretroviral Therapies Daniel Lee, MD Clinical Professor of Medicine UCSD Medical Center Owen Clinic July 14, 2016 This project is supported by the Health Resources and

More information

The impact of antiretroviral drugs on Cardiovascular Health

The impact of antiretroviral drugs on Cardiovascular Health The impact of antiretroviral drugs on Cardiovascular Health José López-Sendón Hospital Universitario La Paz. IdiPaz Madrid. Spain Research grants and honoraria from (research committees, clinical trials,

More information

Special Challenges and Co-Morbidities

Special Challenges and Co-Morbidities Special Challenges and Co-Morbidities Renal Disease/ Hypertension/ Diabetes in African-Americans M. Keith Rawlings, MD Medical Director Peabody Health Center AIDS Arms, Inc Dallas, TX Chair, Internal Medicine

More information

Emerging Considerations in neuroaids Internationally: Events in Acute and Early Infection

Emerging Considerations in neuroaids Internationally: Events in Acute and Early Infection Emerging Considerations in neuroaids Internationally: Events in Acute and Early Infection Igor Grant, M.D. Director, HIV Neurobehavioral Research Center University of California, San Diego Although combination

More information

Efficacy, Safety, and Adherence of TDF/3TC/EFV Once Daily in Virologic-suppressed HIV-infected Children following Switching from NNRTI-based Regimens

Efficacy, Safety, and Adherence of TDF/3TC/EFV Once Daily in Virologic-suppressed HIV-infected Children following Switching from NNRTI-based Regimens O_05 Efficacy, Safety, and Adherence of TDF/3TC/EFV Once Daily in Virologic-suppressed HIV-infected Children following Switching from NNRTI-based Regimens Linda Aurpibul MD. 1, Thition Narkbunnam MD. 2,

More information

D:A:D Study Teaching Material

D:A:D Study Teaching Material D:A:D Study Teaching Material Data Collection of Adverse events of anti-hiv Drugs (D:A:D) study December 2012 - CHIP Background The D:A:D Study, is a prospective cohort study (collaboration) initiated

More information

HIV Prevention. David Cooper, MD, DSc Director and Professor, Kirby Institute University of New South Wales Sydney, Australia

HIV Prevention. David Cooper, MD, DSc Director and Professor, Kirby Institute University of New South Wales Sydney, Australia HIV Prevention David Cooper, MD, DSc Director and Professor, Kirby Institute University of New South Wales Sydney, Australia HIV Care/Prevention Continuum Test Engage, Counsel, Monitor and Support Retain,

More information

Tenofovir plasma exposures and Creatinine Clearance changes in 1st line Regimen of African patients in Cameroon and Senegal: ANRS12115 DAYANA study

Tenofovir plasma exposures and Creatinine Clearance changes in 1st line Regimen of African patients in Cameroon and Senegal: ANRS12115 DAYANA study Abstract O_03 Tenofovir plasma exposures and Creatinine Clearance changes in 1st line Regimen of African patients in Cameroon and Senegal: ANRS12115 DAYANA study M.P. Lê Pharmacy Resident Clinical Pharmacology

More information

Dr Manisha Yapa. Chelsea and Westminster Hospital, London. 19 th Annual Conference of the British HIV Association (BHIVA)

Dr Manisha Yapa. Chelsea and Westminster Hospital, London. 19 th Annual Conference of the British HIV Association (BHIVA) 19 th Annual Conference of the British HIV Association (BHIVA) Dr Manisha Yapa Chelsea and Westminster Hospital, London 16-19 April 2013, Manchester Central Convention Complex The impact of switching to

More information

HIV Treatment Update. Anton Pozniak Consultant Physician, Director of HIV Services Chelsea and Westminster Hospital, London

HIV Treatment Update. Anton Pozniak Consultant Physician, Director of HIV Services Chelsea and Westminster Hospital, London HIV Treatment Update Anton Pozniak Consultant Physician, Director of HIV Services Chelsea and Westminster Hospital, London Guidelines Nuke sparing Nukes Efavirenz placement as the gold standard ARV Role

More information

Dr Marta Boffito Chelsea and Westminster Hospital, London

Dr Marta Boffito Chelsea and Westminster Hospital, London Dr Marta Boffito Chelsea and Westminster Hospital, London Speaker Name Statement Dr Marta Boffito has received travel and research grants from and has been an advisor for Janssen, Roche, Pfizer, ViiV,

More information

Didactic Series. CROI Update - II. Christian B. Ramers, MD, MPH Family Health Centers of San Diego Ciaccio Memorial Clinic 5/28/15

Didactic Series. CROI Update - II. Christian B. Ramers, MD, MPH Family Health Centers of San Diego Ciaccio Memorial Clinic 5/28/15 Didactic Series CROI Update - II Christian B. Ramers, MD, MPH Family Health Centers of San Diego Ciaccio Memorial Clinic 5/28/15 ACCREDITATION STATEMENT: University of California, San Diego School of Medicine

More information

Prima linea: dovremmo evitare i PI nella terapia di prima linea per i loro effetti non desiderati? Giuseppina Liuzzi

Prima linea: dovremmo evitare i PI nella terapia di prima linea per i loro effetti non desiderati? Giuseppina Liuzzi 6 th INFECtivology TOday Paestum 15-16 -17 maggio 2014 Prima linea: dovremmo evitare i PI nella terapia di prima linea per i loro effetti non desiderati? Giuseppina Liuzzi Istituto Nazionale per le Malattie

More information